Clinical Trial Update: The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update for HLX208, a BRAF V600E inhibitor, in refractory primary brain tumors with BRAF mutation after first-line treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Brain Tumor, Primary | Phase 2 | Status: UNKNOWN